Clinical Trial Update: Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) [Phase 1, Phase 2]

View source ↗

Summary

This report summarizes the completion and results posting of a Phase 1/2 trial evaluating Bendamustine plus Bortezomib in indolent non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Bortezomib (bortezomib)

Snippet

Sponsor: Peter Moosmann | Conditions: Lymphoma, Non-Hodgkin | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-04-03